New injection aims to help obese heart failure patients lose weight and feel better

NCT ID NCT06391710

Ongoing Disease control Sponsor: Fujian Shengdi Pharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase 2 study tests an injectable drug called HRS9531 in 203 obese adults with a type of heart failure where the heart pumps normally but is stiff. Participants receive either the drug or a placebo for 52 weeks. The main goals are to see if the drug helps with weight loss and improves heart-related quality of life.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: HRS9531 injection
What this could lead to: If successful, this could point toward a new treatment option that helps obese people with heart failure lose weight and feel better day-to-day.
What could go wrong: This is an early Phase 2 trial with only 203 participants, so results may not apply to everyone. The drug may not improve heart failure outcomes or could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEART FAILURE WITH PRESERVED EJECTION FRACTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diastolic heart failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEART FAILURE WITH PRESERVED EJECTION FRACTION

Contacts and locations

Locations

Beijing Anzhen Hospital, Capital Medical University

Beijing, Beijing Municipality, 100020, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.